The Asia-Pacific oncolytic virus therapy market is estimated to grow at a CAGR of more than 14% during the forecast period. The Asia-Pacific region is estimated to be a potential market for oncolytic virus therapies due growing aging population coupled with increasing prevalence and incidence of cancer across the major economies of the region. Moreover, increasing healthcare expenditure and infrastructure, and research on novel therapies for the treatment of the cancer are further supporting the market growth of the region.

Request a Free Sample of Asia-Pacific Oncolytic Virus Therapy Market: https://www.omrglobal.com/request-sample/asia-pacific-oncolytic-virus-therapy-market

Furthermore, one of the factors surging the prevalence of cancer is the aging population. Aging weakens the immune system of the body; thereby, increasing the chances of development of chronic diseases such as cancer. With the age dynamics, cancer cases in Asia-Pacific are expected to grow, thereby driving the demand for novel cancer therapies such as oncolytic virus therapies.

A full Report of Asia-Pacific Oncolytic Virus Therapy Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-oncolytic-virus-therapy-market

The global oncolytic virus therapy market in Asia-Pacific is segmented into India, China, Japan and Rest of Asia-Pacific. China held the highest market share in the Asia-Pacific market. The market in China is growing at a CAGR of 14.5%. The market growth in China is attributed to the increasing prevalence of cancer that has encouraged the researchers and scientists in China to work on the development of novel therapies for the treatment of cancer. Moreover, significant activities have been witnessed in the Chinese oncolytic virus therapies market in recent years. For instance, in 2018, Transgene SA signed a series of agreements with Tasly Biopharmaceuticals Co. Ltd. for the development of two immunotherapies, T601 and T101, by the Transgene-Tasly joint venture in China.
Further, the Asia-Pacific oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share in 2018. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share.

Asia-Pacific Oncolytic Virus Therapy Market Segmentation

By Product

• HSV-Based Oncolytic Virus
• Adenoviruses-Based Oncolytic Virus
• Vaccinia Virus-Based Oncolytic Virus
• Vesicular Stomatitis Virus-Based Oncolytic Virus
• Newcastle Disease Virus- Based Oncolytic Virus
• Others

By Application

• Prostate Cancer
• Breast Cancer
• Ovarian Cancer
• Melanoma
• Others

Regional Analysis

• China
• Japan
• India
• Rest of Asia-Pacific

Company Profiles

• Oncolys BioPharma Inc.
• Otsuka Pharmaceuticals Co. Ltd.
• Shanghai Sunway Biotech Co., Ltd.
• SillaJen, Inc.
• Takara Bio Inc.
• Viralytics Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-oncolytic-virus-therapy-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404